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Abstract 
 
The use of new psychoactive substances and the new patterns of drug use can have important public health and policy implications. 
Few countries have monitoring systems that are sensitive to this new phenomenon in the drug field, but methodological difficulties to 
detect them are considerable. Nonetheless, the importance of identifying potential new threats is widely recognized. The European 
Union’s Early-Warning System (EWS) provides a quick-response mechanism to the emergence of new psychoactive substances on 
the drug scene. The European Council’s decision on new psychoactive substances establishes a mechanism for the rapid exchange 
of information on new drugs. It also provides the possibility to trigger a formal risk assessment process, the findings of which may 
lead to a political decision to place new substances under control across the European Union. 
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Abbreviations 
EWS - Early-Warning System, THC – Tetrahydrocannabinol, EMCDDA - European Monitoring Center for Drugs and Drug Addiction 
Introduction 
Since the establishment of the new early-
warning system (EWS) in 1997 [1], more than 90 
substances have been reported. Most of the new 
synthetic substances have stimulant properties, while only 
a few produce hallucinogenic effects.  
For the first time ever, in 2008, a synthetic 
cannabinoid (JWH-018, Naphthalen-1-yl-(1-pentylindol-3-
yl) methadone) was reported through the early-warning 
system. The appearance of synthetic cannabinoids marks 
the latest stage in the development of designer drugs: 
from those based on fentanyl in the 1980s to ring-
substituted phenethylamines in the late 1980s and 
tryptamines in 1990s, to piperazines and cathinone 
derivatives in the 2000s [2]. There are over a hundred 
compounds with cannabinoid receptor activity and it can 
be assumed that new substances from different chemical 
groups will continue to appear on the drug scene. All this 
presents a constant challenge to public health and law 
enforcement agencies.  
 
Synthetic Cannabinoids  
Synthetic cannabis products are psychoactive 
herbal mixtures which have similar effects to those of 
cannabis, when inhaled. Based on patients’ clinical 
medical history, smoking these substances produces 
cannabinoid-like effects, although they do not contain 
THC (delta-9-tetrahydrocannabinol -  the main 
psychoactive substance of cannabis plant) [6].  
A large and complex variety of synthetic 
cannabinoids, most often cannabicyclohexanol, JWH-018, 
JWH-073 (naphthalen-1-yl-(1-butylindol-3-yl)methanone), 
CP 47 497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5-(2-
methyloctan-2-yl)phenol), HU-210 (1,1-Dimethylheptyl-11-
hydroxy-tetrahydrocannabinol) are used in an attempt to 
avoid the laws making cannabis illegal, thus conferring 
synthetic cannabis the status of a designer drug. Designer 
drugs are pharmaceuticals, created or reformulated to 
bypass current laws, by modifying the molecular 
structures of drugs (Fig. 1). The goal is to satisfy the 
users’ demand for drugs that can be obtained without 
prescriptions or other legal constraints [2,4-5].   
 
 
 
 
 
 
 
 
 
Fig. 1 JWH-018 formula (1-pentyl-3-(1-naphthoyl) indole) 
Molecular formula: C24H23NO 
Molecular weight: 341.5 g/mol 
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Although synthetic cannabis does not produce 
positive results in drug tests for cannabis, it is possible to 
detect its metabolites in human urine. The synthetic 
cannabinoids contained in synthetic cannabis products 
have been declared illegal in many European countries.  
 
Availability of Spice products 
A European survey that took place in 2008, 
conducted by the European Monitoring Center for Drugs 
and Drug Addiction (EMCDDA), identified Spice products 
in 21 out of the 30 participating countries. For the purpose 
of the survey, “identification” means that these types of 
products were available in some form in the country.  
JWH or CP compounds were identified by 
forensic/toxicological analysis in 8 out of 21 countries 
where Spice products were available: Austria, Germany, 
Finland, France, Hungary, Poland, Slovenia and the 
United Kingdom. The substances identified were: JWH-
018; CP 47 497 - C8 homologue; CP 47 497; JWH-073 
(naphthalen-1-yl-(1-butylindol-3-yl) methanone) [2]. 
 
The composition of Spice products 
The products marketed on the internet and in 
specialized shops under the names “Spice”, "Smoke", 
"Scence", "Yucatan Fire", or "Skunk" and advertised as an 
exotic incense blend which releases a rich aroma, along 
with the disclaimer not for human consumption, have 
been widely reported as producing many of the 
physiological effects of marijuana.  
The labels on the packages indicate that the 
products are composed of as many as 14 ingredients of 
plant origin, with every package weighting between 0.4–
3.0 g. Synthetic ingredients are not mentioned in the 
product information.  
While at least two of the ingredients — 
Pedicularis densiflora and Leonotis leonurus — may have 
some psychoactive effect, little is known about the 
pharmacology and toxicology of the plant materials 
purportedly contained in spice products (Table 1). All of 
these products contain differing varieties of herbs and 
other botanicals [2-3]. 
 
                    Table 1. Herbal components of Spice products 
Common name  Species  Family 
Beach bean  Canavalia maritima, syn. C 
rosea 
Fabaceae 
White and blue water lily   Nzmphaea alba and N. caerulea  Nymphaeaceae 
Dwarf skullcap  Scutellaria nana  Lamiacae 
Indian warrior   Pedicularis densiflora  Orobanchaceae  
Lion’s ear/tail, Wild dagga   Leonotis leonuru  Lamiacae  
Maconha brava’  Zornia latifolia or Z. diphylla  Fabaceae 
Blue/Sacred lotus   Nelumbo nucifera  Nelumbonaceae 
Honeyweed/Siberian motherwort   Leonurus sibiricus  Lamiaceae 
Marshmallow   Althaea officinalis  Malvaceae 
Dog rose/Rosehip  Rosa canina  Roseceae 
 
In 2008, spice products, as well as various other 
spice-like herbal mixes, could be purchased from online 
shops, and were available in specialized shops selling 
“legal highs” in at least nine EU Member States (Czech 
Republic, Germany, Latvia, Lithuania, Luxembourg, 
Austria, Poland, Portugal, Romania, United Kingdom). 
Without a legislative framework to control its distribution 
and insufficient detection methods, the law enforcement 
agencies faced a significant challenge in addressing the 
problem of synthetic cannabinoids.  
Extensive forensic investigations have been 
undertaken by EU Member States in order to identify the 
psychoactive ingredients of spice products. In December 
2008, Germany and Austria detected the synthetic 
cannabinoid JWH-018. The chemical structure of JWH-
018 differs substantially from that of tetrahydrocannabinol 
(THC), the main active principle in all cannabis products. 
In experimental animals, JWH-018 produces the same 
effects as THC and has been reported to be more potent. 
Earlier, in 2009, a second synthetic cannabinoid named 
CP 47 497, and three of its homologues were detected in 
spice samples in Europe.  Some reports indicate that 
JWH-018 binds to the CB1 receptor (cannabinoid 
receptor) with even greater affinity than marijuana [3].  
 
Effects of synthetic cannabinoids  
The reported pharmacological effects of 
synthetic cannabinoids smoked are very similar to that of 
marijuana. This comes as no surprise, given that Spice 
and K2 are THC agonists - meaning they chemically bind 
to the same brain receptor (CB1) and trigger many similar 
responses as marijuana. The physiological effects of 
synthetic cannabinoids include: increased heart rate and 
blood pressure, altered state of consciousness, 
perceptual alterations (time distortion), intensification of 
sensory experiences, impaired short-term memory [7]. 
 
Laws regarding synthetic cannabinoids  
Responding to potential health concerns, the 
Member States have taken diverse legal actions to ban or 
otherwise control spice products and related compounds 
(Table 2). Germany used its emergency legislation for 
narcotics to control for one year five synthetic 
cannabinoids found in spice products. France classified Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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as narcotics six synthetic cannabinoids found in spice 
products. Austria used its medicines act to prohibit 
smoking mixes containing six synthetic cannabinoids from 
being imported or marketed in the country. Luxembourg 
decided to control various synthetic cannabinoids as 
psychotropic substances. Poland amended the narcotic 
law, placing under control JWH-018 and two of the 
claimed herbal ingredients of spice [2]. 
 
Table 2. Legislative measures for incriminating synthetic cannabinoid at European level 
Country  Legislative measures 
Austria  
 
On the 18th of December 2008, the Austrian Ministry of Health announced that Spice would 
be controlled under Paragraph no. 78 of Austrian drug law, on the grounds that it contains an 
active substance which affects the functions of the body, and the legality of JWH-018 is under 
review 
Germany  
 
JWH-018, CP 47,497 and the C6, C8 and C9 homologues of CP 47,497 are illegal in 
Germany since the 22nd of January 2009 
Finland  
 
Spice blends are classified as a medicine in Finland and, therefore, it is illegal to order them 
without a prescription 
France  
 
JWH-018, CP 47,497 (and its homologues) and HU-210 were all made illegal in France on 
the 24th of February 2009 
Ireland  
 
From June 2010, JWH-018, along with a variety of other designer drugs have been declared 
illegal 
Latvia  
 
JWH-018, JWH-073, CP 47,497 (and its homologues) and HU-210 are all banned in Latvia as 
well as leonotis leonurus 
Poland  
 
JWH-018 and many of the herbs mentioned on the ingredient lists of Spice and similar 
preparations were made illegal in May 2009 
Romania   Spice was made illegal in Romania on the 15th of February 2010, Governmental Ordinance 
no. 6/2010  
Sweden  
 
CP 47,497-C6, CP 47,497-C7, CP 47,497-C8, CP 47,497-C9, JWH-018, JWH-073 and HU-
210 were all made illegal in Sweden on the 15th of September 2009  
United Kingdom  
 
Spice was legal in the United Kingdom until December 2009, when it was classified as a 
Class B drug 
 
Conclusions 
Spice and other herbal products are often 
referred to as legal highs. It appears that most of the 
ingredients listed on the packaging are actually not 
present in the Spice products and it is seems likely that 
the psychoactive effects reported are most probably due 
to added synthetic cannabinoids, which are not shown on 
the label. Different amounts or combinations of these 
substances seem to have been used in different Spice 
products to produce cannabis-like effects. It is possible 
that the substances from these or other chemical groups, 
with a cannabinoid agonist or other pharmacological 
activity could be added to any herbal mixture. So far, the 
Spice and Spice-like preparations in Europe have been 
found to contain at least nine new substances from three 
chemically distinct groups of synthetic cannabinoids 
(JWH, CP and HU). This presents an ongoing challenge, 
not only for their forensic and toxicological identification, 
but also for risk assessments and the development of 
possible control strategies. 
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